Agile Therapeutics Inc. (NASDAQ:AGRX) shares fell 5.2% during trading on Wednesday . The stock traded as low as $6.99 and last traded at $7.09, with a volume of 63,974 shares. The stock had previously closed at $7.48.

Several brokerages have recently commented on AGRX. Cantor Fitzgerald reiterated a “buy” rating on shares of Agile Therapeutics in a research report on Tuesday, May 31st. Zacks Investment Research lowered Agile Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. Finally, FBR & Co reiterated a “buy” rating on shares of Agile Therapeutics in a research report on Friday, June 17th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $15.17.

The stock has a 50 day moving average of $7.50 and a 200 day moving average of $6.78. The company’s market cap is $208.38 million.

Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings data on Monday, May 9th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.11. On average, analysts forecast that Agile Therapeutics Inc. will post ($1.12) earnings per share for the current year.

An institutional investor recently raised its position in Agile Therapeutics stock. Marshall Wace LLP boosted its position in shares of Agile Therapeutics Inc. (NASDAQ:AGRX) by 4.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 129,769 shares of the specialty pharmaceutical company’s stock after buying an additional 6,099 shares during the period. Marshall Wace LLP owned approximately 0.58% of Agile Therapeutics worth $1,267,000 as of its most recent filing with the SEC.

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.